To evaluate and investigate the particular processes through which ACTA2, FLNA, TAGLN, and TPM1 contribute to the progression of BLCA, more in vitro and in vivo investigations and clinical samples are required. The gene discussed is TAGLN; the disease is bladder transitional cell carcinoma.